Market Access

The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)

Drug Channels

This week, we're rerunning some popular posts while we prepare for Friday's live video webinar: PBM Industry Update 2026: Trends, Challenges, and What's Ahead .

Market Access Read full story

pharminent April 6, 2026 (Last updated: April 6, 2026)

Drug Channels

This week, we’re rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead .

Market Access Read full story

Related Stories

GSK’s Nucala secures NICE COPD endorsement

Medicare Advantage Out-of-Pocket Limits: Variation and Trends

France ‘first EU country to cover obesity drugs’

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise